UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2016-03, Vol.17 (3), p.367-377

2016

Volltextzugriff (PDF)

Final 5-Year Results of Z-FAST Trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole

Cancer, 2012-03, Vol.118 (5), p.1192-1201

2012

Volltextzugriff (PDF)

Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer

Journal of clinical oncology, 2007-03, Vol.25 (7), p.829-836

2007

Volltextzugriff (PDF)

Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer

Journal of clinical oncology, 2006-09, Vol.24 (27), p.4441-4447

2006

Volltextzugriff (PDF)

Final 5‐year results of Z‐FAST trial

Cancer, 2012-03, Vol.118 (5), p.1192-1201

2012

Volltextzugriff (PDF)

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Breast cancer research : BCR, 2019-03, Vol.21 (1), p.39-39, Article 39

2019

Volltextzugriff (PDF)

Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer

Journal of clinical oncology, 2003-03, Vol.21 (5), p.807-814

2003

Volltextzugriff (PDF)

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2014-09, Vol.32 (25), p.2765-2772

2014

Volltextzugriff (PDF)

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

Clinical colorectal cancer, 2012-06, Vol.11 (2), p.101-111

2012

Volltextzugriff (PDF)

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial

JAMA oncology, 2017-07, Vol.3 (7), p.906

2017

Volltextzugriff (PDF)

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

The Lancet infectious diseases, 2019-09, Vol.19 (9), p.1001-1012

2019

Volltextzugriff (PDF)

A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer

Clinical breast cancer, 2011-04, Vol.11 (2), p.121-128

2011

Volltextzugriff (PDF)

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2017-12, Vol.18 (12), p.1688-1700

2017

Volltextzugriff (PDF)

A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation

Lung cancer (Amsterdam, Netherlands), 2013-03, Vol.79 (3), p.307-311

2013

Volltextzugriff (PDF)

Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II .beta. isoform

Biochemistry (Easton), 1991-10, Vol.30 (41), p.9953-9961

1991

Volltextzugriff (PDF)

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen‐independent prostate carcinoma

Cancer, 2004-02, Vol.100 (4), p.746-750

2004

Volltextzugriff (PDF)

Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study

Journal of clinical oncology, 1993-01, Vol.11 (1), p.161-165

1993

Volltextzugriff (PDF)

A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer

Clinical breast cancer, 2011-01, Vol.1 (1), p.1-8

2011

Volltextzugriff (PDF)

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

Clinical breast cancer, 2012-10, Vol.12 (5), p.322-330

2012

Volltextzugriff (PDF)

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4504-4504

2013

Volltextzugriff (PDF)

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

Journal of clinical oncology, 1991-05, Vol.9 (5), p.721-728

1991

Volltextzugriff (PDF)

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin

Cancer research (Chicago, Ill.), 1995-03, Vol.55 (6), p.1339-1346

1995

Volltextzugriff (PDF)

The Fate of the Bladder in Patients with Metastatic Bladder Cancer Treated with Cisplatin, Methotrexate and Vinblastine: A Northern California Oncology Group Study

The Journal of urology, 1985-12, Vol.134 (6), p.1118-1121

1985

Volltextzugriff (PDF)

Dissociation of Antitumor Potency from Anthracycline Cardiotoxicity in a Doxorubicin Analog

Science (American Association for the Advancement of Science), 1985-06, Vol.228 (4707), p.1544-1546

1985

Volltextzugriff (PDF)

Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase IIα messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone

Cancer research (Chicago, Ill.), 1995-11, Vol.55 (21), p.4962-4971

1995

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(35)
Science & Technology
(34)
Life Sciences & Biomedicine
(33)
Oncology
(25)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Female
(20)
Middle Aged
(20)
Aged
(17)
Pharmacology. Drug Treatments
(16)
Adult
(15)
Antineoplastic Agents
(15)
Male
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Chemotherapy
(10)
General Aspects
(10)
Tumors
(10)
Aged, 80 And Over
(8)
Breast Neoplasms - Drug Therapy
(7)
Drug Administration Schedule
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Final 5-Year Results of Z-FAST Trial: Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole

Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer

Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer

Final 5‐year results of Z‐FAST trial

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer

Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation

Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II .beta. isoform

Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen‐independent prostate carcinoma

Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study

A Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel With or Without Trastuzumab in Metastatic Breast Cancer

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin

The Fate of the Bladder in Patients with Metastatic Bladder Cancer Treated with Cisplatin, Methotrexate and Vinblastine: A Northern California Oncology Group Study

Dissociation of Antitumor Potency from Anthracycline Cardiotoxicity in a Doxorubicin Analog

Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase IIα messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone

Suchergebnisse filtern